Ranbaxy shares recover on value buying after steep falls

Shares in Ranbaxy Laboratories gain as much as 3.3 percent, after falling 26 percent over Friday and Monday following a ban by U.S. drug regulator on more of its products.

"Valuation wise, the stock looks good at these levels. It has fallen a lot and I don't think it will fall beyond 300 rupees," said Suresh Parmar, head, institutional equities at KJMC Capital Markets.

At 10:34 a.m., shares in Ranbaxy were up 2.41 percent at 316.60 rupees, outperforming the broader Nifty, which was up 0.24 percent.


  • RBI should make it must for banks to disclose loans refinanced under 5/25 scheme

    There is reasonable doubt that banks are using the 5/25 scheme to postpone dealing with bad loans.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Roopen Roy

Bitcoins will spark India’s financial innovation

Often, when you string together two pieces of seemingly unconnected ...

Rajgopal Nidamboor

The power of detached thinking

Dispassionate thinki­ng holds the discriminating embroidery of perceptive focus and ...

Dharmendra Khandal

Mosquitoes are a menace, but part of eco system too

Who can deny that mosquitoes are a menace? The buzz ...


William D. Green

Chairman & CEO, Accenture